Cipyne

Cipyne is a pre-clinical stage biotechnology company focused on developing first-in-class small molecule therapeutics that target cation-chloride cotransporters (CCCs) to treat neurological and psychiatric disorders. The company's proprietary platform leverages deep expertise in the structural biology and pharmacology of CCCs, which are critical regulators of ionic balance in the brain. By restoring chloride homeostasis, Cipyne aims to address the underlying pathophysiology of conditions such as epilepsy, neuropathic pain, and schizophrenia. The company is currently advancing its lead programs through lead optimization and early development stages. Cipyne's approach represents a novel mechanism of action in the neuro-therapeutic space, potentially offering hope for patients with treatment-resistant CNS conditions.